Prolonged, low-dose mATG with a short course of CTLA4-Ig and induction mATG achieves long-term graft survival and favors the emergence of Tregs.

<p><b>A.</b> Kaplan-Meier graph depicting fully MHC-mismatched skin allograft survival following the administration of pld-mATG, i-mATG, i-mATG plus pld-mATG, or no treatment. <b>B.</b> Kaplan-Meier graphs depicting fully MHC-mismatched skin allograft survival in mice administered i-mATG alone, CTLA4-Ig alone,CTLA4-Ig in combination with i-mATG with/without pld-mATG, or no treatment. <b>C.</b> Representative pictures of skin graft from untreated (left panel) and i-mATG plus CTLA4-Ig and pld-mATG-treated mice (right panel). <b>D/E.</b> Bar graphs depicting absolute numbers of CD4⁺ and CD8⁺ cells 7–10 days post-transplantation in mice administered either i-mATG, pld-mATG, CTLA4-Ig or no treatment. <b>F.</b> Bar graphs depicting absolute numbers of CD4⁺CD25⁺FoxP3⁺ cells (Tregs) 7–10 days post-transplantation in mice administered either i-mATG, pld-mATG, CTLA4-Ig or no treatment. Data are representative of ≥3 independent experiments using ≥3 mice per group per timepoint studied.